NCT04020575View on ClinicalTrials.gov

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

PHASE1RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

January 31, 2025

Study Completion Date

January 15, 2035

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells

huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).

BIOLOGICAL

huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D

huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D

Trial Locations (1)

91010-3000

RECRUITING

City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
collaborator

City of Hope Medical Center

OTHER

lead

Minerva Biotechnologies Corporation

INDUSTRY